Trial of Romidepsin and Bortezomib for Multiple Myeloma

NCT ID: NCT00765102

Last Updated: 2019-11-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-01
• Study Completion Date: 2010-03-01

Brief Summary

This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomib non-resistant.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Romidepsin + Bortezomib

Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.

Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.

Group Type: EXPERIMENTAL

Bortezomib

Intervention Type: DRUG

Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.

Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.

Romidepsin

Intervention Type: DRUG

Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.

Interventions

Bortezomib

Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.

Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.

Intervention Type: DRUG

Romidepsin

Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.

Intervention Type: DRUG

Other Intervention Names

VELCADE®; ISTODAX®; depsipeptide; FK228

Eligibility Criteria

Inclusion Criteria

Patients must fulfill all of the following criteria to be eligible for study participation:

• Male or female patients aged ≥ 18 years old
• Has given voluntary written informed consent before any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care
• Previously diagnosed with multiple myeloma (MM) based on standard criteria as follows:

• Major criteria:

1. Plasmacytomas on tissue biopsy.

2. Bone marrow plasmacytosis (>30% plasma cells).

3. Monoclonal immunoglobulin spike on serum electrophoresis IgG >3.5 g/dL or IgA >2.0 g/dL; kappa or lambda light chain excretion >1 g/day on 24 hour urine protein electrophoresis

• Minor criteria:

1. Bone marrow plasmacytosis (10 to 30% plasma cells)

2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria

3. Lytic bone lesions.

4. Normal IgM <50 mg/dL, IgA <100 mg/dL or IgG <600 mg/dL

Any of the following sets of criteria will confirm the diagnosis of MM:

• Any two of the major criteria
• Major criterion 1 plus minor criterion 2, 3, or 4.
• Major criterion 3 plus minor criterion 1 or 3.
• Minor criteria 1, 2, and 3 or 1, 2, and 4.
• Currently has MM with:

o Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of >=1 gm/dL and/or urine monoclonal immunoglobulin spike of >=200 mg/24 hours, or evidence of lytic bone disease

• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
• Life-expectancy > 3 months
• All women of childbearing potential must use an effective barrier method of contraception. Male patients should use a barrier method of contraception during the treatment period and for 3 months thereafter
• Patients must meet the following laboratory criteria at Baseline (Day 1 of Cycle 1, before study drug administration):

• Platelet count ≥ 100*10^9/L
• Absolute neutrophil count ≥ 1.5*10^9/L
• OR if the bone marrow is extensively infiltrated
• Platelet count ≥ 75*10^9/L
• Absolute neutrophil count ≥ 1.0*10^9/L
• Patients must meet the following laboratory criteria at the Screening visit conducted within 14 days of enrollment (Day 1, Cycle 1):

• o Aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 3.0*upper limit of normal (ULN)
• Serum bilirubin ≤ 2.0*ULN
• Calculated or measured creatinine clearance: ≥30 mL/minute. Patient with a creatinine >10mL/min and <30 mL/min due to significant myelomatous involvement of the kidneys may be enrolled in the study after receipt of approval from the lead investigator and sponsor
• Serum potassium ≥ 3.8 mmol/L
• Serum magnesium >1.8 mg/dL
• Serum phosphorus ≥ lower limit of normal (LLN)

• Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
• POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes)
• Plasma cell leukemia
• Primary amyloidosis
• Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
• Severe hypercalcemia, i.e., serum calcium ≥14 mg/dL (3.5 mmol/L)
• Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
• Other concurrent severe and/or uncontrolled medical or psychiatric conditions.
• Concomitant use of drugs that may cause a prolongation of the QTc
• Concomitant use of CYP3A4 inhibitors
• Patients who have hypersensitivity to bortezomib, boron or mannitol
• Patients who are pregnant or breast-feeding
• Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff

Exclusion Criteria

Patients are ineligible for entry if any of the following criteria are met:

• Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or thalidomide, lenalidomide, arsenic trioxide, bortezomib, or glucocorticosteroids within 3 weeks prior to the first dose of romidepsin
• Prior major surgery within 3 weeks prior to the first day of treatment
• Use of any investigational agent within 4 weeks of study entry
• Prior therapy with romidepsin
• Any known cardiac abnormalities such as:

• Congenital long QT syndrome;
• QTc interval ≥ 500 milliseconds;
• Myocardial infarction within 6 months of Day 1. Subjects with a history of myocardial infarction between 6 and 12 months prior to the first day of cycle one who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;
• Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min);
• Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
• An ECG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
• Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by Multi Gated Acquisition Scan (MUGA scan) or <50% by echocardiogram and/or MRI;
• A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
• Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tina Neilson

Role: STUDY_DIRECTOR

Celgene Corporation

Locations

Loma Linda University Cancer Center

Loma Linda, California, United States

Desert Cancer Care, Inc

Rancho Mirage, California, United States

Santa Barbara Hematology Oncology Medical Group, Inc.

Santa Barbara, California, United States

James R Berenson, MD, Inc.

West Hollywood, California, United States

Georgia Cancer Specialists I, PC

Atlanta, Georgia, United States

Center for Cancer and Blood Disorders

Bethesda, Maryland, United States

Mecklenburg Medical Group

Charlotte, North Carolina, United States

Baylor Sammons Cancer Center

Dallas, Texas, United States

Dallas Oncology Consultants, P.A.

Duncanville, Texas, United States

Oncology Consultants, P.A

Houston, Texas, United States

Central Utah Clinic, PC

Provo, Utah, United States

Virginia Mason Medical Centre

Seattle, Washington, United States

Countries

United States

References

Berenson J, et al. A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. Presented at 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orlando FL. Abstract No. e10908. J Clin Oncol 2009;27(15s)

Reference Type: BACKGROUND

Other Identifiers

GPI-08-0006

Identifier Type: -

Identifier Source: org_study_id